CD7 specific CAR T cell therapy - Hebei Taihe Chunyu Biotechnology
Latest Information Update: 02 Jan 2025
Price :
$50 *
At a glance
- Originator Hebei Taihe Chunyu Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haematological malignancies
Most Recent Events
- 06 Dec 2024 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater, In children, In adolescents, In adults, In the elderly) in China (IV) (NCT06720324)